Buyout news for Amarin

Quote






Great, I always wanted to sell fish oil, the only thing that would make it better is if we had some snake oil to go with it.................oh wait, that's what we are going to sell it with.........my bad.
 






Anonymous said:
Great, I always wanted to sell fish oil, the only thing that would make it better is if we had some snake oil to go with it.................oh wait, that's what we are going to sell it with.........my bad.
Click to expand...

You'll sell whatever is in your bag, loser, or you'll be fired.

New AstraZeneca boss 'planning to launch cash bid' for US biopharmaceutical group Amarin

Read more: http://www.dailymail.co.uk/money/ma...harmaceutical-group-Amarin.html#ixzz2ADZVDs2h

"AstraZeneca's new boss Pascal Soriot didn’t mess about when on his first day in the job he announced the suspension of the drugs group’s £2.8bn share buy-back programme.
Shareholders were obviously miffed, but analysts took it as a definite sign that he wanted to save the cash for earnings enhancing acquisitions.
Soriot recently spent up to £169m on the rights to an experimental kidney drug, but rumours now suggest he has something much bigger up his sleeve.

AZ’s shares shed 38p to 2900p ahead of tomorrow’s third-quarter trading statement.
The fall was accompanied by speculation Soriot is planning to launch a cash bid for US biopharmaceutical group Amarin, whose shares moved against the trend on Wall Street yesterday with an early gain to $11.61.
AstraZeneca, along with other larger pharmaceutical companies such as Merck, Pfizer, Abbott and Eli Lilly, would apparently love to get their hands on Amarin for Vascepa, a prescription medicine which helps with the treatment for cardiovascular disease. It is the group’s first FDA approval product.

US analysts are of the opinion that Amarin’s days of independence are numbered.
They reckon that Amarin now stands at the crossroads and appears to be waiting for a large pharmaceutical company, with a substantial cardiovascular or diabetes sales force, to come and swallow it whole.
William Tanner, analyst at Lazard Capital Markets, currently has a target price of $26 on Amarin as has Canaccord Genuity’s Ritu Baral. What does that tell you?"
 


















Might make sense for R&D. The CV/GI cupboard is bare here in Mölndal...if they have anything half-way promising in early phase in addition to vascepa...vascepa...jesus where do they get these names....
 






Mr. Soriot: (I wonder why I'm helping you, I hate your new company. Total assholes everywhere)



The answer to the new blockbuster you seek is in God's infinite gifts to mankind, whom he loves with infinite Love. We do not understand the mysteries of the human body, at all. Not anywhere close. We know about 1% of what is going on in the chemistry of living organisms. We have NO IDEA how it works: we don't know what life is any better than the Bible's explanation explaining that God breathed life into a handful of dust. But you think you do? Think of any drug you've heard of anyone selling: it was discovered by accident. Serendipity. Not in any laboratory.

When you can come off of your arrogance (if remotely possible, since you're rich) and seek the Wisdom of God, and humble yourself, He may provide for you. And your shareholders. He is a Mountain of Provision:

http://www.rainforesteducation.com/medicines/PlantMedicines/rfmedicines.htm
 












Another patent for Vascepa issued today. I think that makes 8 patents so far. More are on the way.

Amarin Announces U.S. Patent 8,298,554 Issuance for Vascepa(TM)
Issuance for '885 Application

Press Release: Amarin Corporation
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 30, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering the pharmaceutical composition of Amarin's VascepaTM (icosapent ethyl) capsules based on U.S. Patent Application Serial No. 12/769,885. On July 2, 2012, Amarin announced the issuance of a Notice of Allowance for claims under this application. The newly issued patent, U.S. Patent No. 8,298,554, is titled "Highly Stable EPA in a Capsule."
This issued patent has a term that expires no earlier than in 2030. Amarin plans to list this patent in the U.S. Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.
"This patent issuance represents another step forward in Amarin's effort to protect the commercial potential of Vascepa," said Joseph Zakrzewski, Amarin's Chairman and Chief Executive Officer. "Amarin's goal is to protect the commercial potential of Vascepa to beyond 2030 through patent protection, regulatory exclusivity and trade secrets and by taking advantage of manufacturing barriers to entry."
Amarin now has eight U.S. patents either issued or allowed as well as over 30 additional patent applications currently in prosecution in the United States. Amarin is also pursuing patent applications related to Vascepa in multiple jurisdictions outside the United States, including the application for Amarin's MARINE method of use patent in Europe for which Amarin has announced receipt of an Intention to Grant letter.
 




































Boy, AZ will be pissed if they buy this POS company and they realize the company hired mostly people AZ canned over this past year. Stock dropped (even worse than most ) today. AZ could probably pull a hostile takeover.
 






You stupid prick, I'll bet you this fish oil does more in the first 6 months than Brillinta does all year. Now go pull up touchstone and act like you're working. Go go lol.
 






you know what, you're right. I will go ahead and continue to click through touchstone in a carefully calculated fashion that would make one think that I am actually engaging in conversation with the physician whose fat ass gatekeeper wont let anyone talk to him except 2x a year when I am shoving Panera down her piehole. Lord knows we all for right now have a good gig here even if we are forced to play dress-up and pretend we are out there movin da needle because we are as wanted in our customer's office as much as herpes on your prom night. The new Amarin sales team is no different. They are just trying to survive in a market/career that is soon becoming opsolete. I'm sure they are not looking to come back to the company that raped many of them of their dignity. Especially because I hear they aren't offering the reps much as far as salary goes. So they are forced to sell fish oil to the same asshole doctors who didn't want to hear about Crestor for about 1/3 of what they were making.
 












Top Bottom
Back
Quote